Villoria Erica, Lara Laura
Universidad Autónoma de Chile, Santiago, Chile.
Rev Med Chil. 2018 Mar;146(3):300-307. doi: 10.4067/s0034-98872018000300300.
Depression and anxiety are common in patients with cancer.
To adapt and validate the Hospital Anxiety and Depression Scale (HADS) for adult Chilean cancer patients, and to provide information about their prevalence of anxiety and depression.
Two hundred fifteen patients with cancer answered an adapted version of HADS for Chilean population. The language adjustment of the scale was carried out with the opinions of 10 expert linguists and with a pilot study on 17 cancer patients. The Depression and Anxiety subscales of the DASS-21 were also applied to verify the convergent validity of HADS: Results: The confirmatory factor analysis indicated that the data fits the model of two correlated factors (anxiety and depression), χ2 = 98.608; df = 76;p < 0.05; χ2/df= 1.23, RMSEA = 0.037; CFI = 0.99; TLI = .98. Reliability analysis showed an adequate internal consistency of both subscales (.76 for anxiety and .84 for depression) and the general scale (.87). Correlations between HADS and DASS-21 scores were significant for both anxiety (r =.514, p < 0.001) and depression (r = 0.600, p < 0.001). Prevalence rates were approximately 30% for depression (actual = 12%, possible = 22.8%) and approximately 20% for anxiety (actual = 7%, possible = 8.4%).
We conclude that HADS is a reliable and valid instrument for screening clinically relevant anxiety and depression symptoms in Chilean cancer patients.
抑郁症和焦虑症在癌症患者中很常见。
对医院焦虑抑郁量表（HADS）进行改编并验证其适用于智利成年癌症患者，并提供有关其焦虑和抑郁患病率的信息。
215名癌症患者回答了针对智利人群改编版的HADS。量表的语言调整是在10位专家语言学家的意见以及对17名癌症患者的预试验基础上进行的。还应用了抑郁焦虑量表（DASS-21）的抑郁和焦虑分量表来验证HADS的收敛效度。结果：验证性因素分析表明数据符合两个相关因素（焦虑和抑郁）的模型，χ2 = 98.608；df = 76；p < 0.05；χ2/df = 1.23，RMSEA = 0.037；CFI = 0.99；TLI = 0.98。信度分析显示两个分量表（焦虑分量表为0.76，抑郁分量表为0.84）以及总量表（0.87）都具有足够的内部一致性。HADS与DASS-21得分之间的焦虑相关性（r = 0.514，p < 0.001）和抑郁相关性（r = 0.600，p < 0.001）均显著。抑郁症患病率约为30%（实际为12%，可能为22.8%），焦虑症患病率约为20%（实际为7%，可能为8.4%）。
我们得出结论，HADS是一种可靠且有效的工具，可用于筛查智利癌症患者临床上相关的焦虑和抑郁症状。
